ALCMI, Champions Oncology, and ROS1ders to Launch Clinical Study

Posted by ALCF Staff on August 15th, 2017
No Comments

The Addario Lung Cancer Medical Institute (ALCMI), and Champions Oncology (NASDAQ: CSBR), a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, announce a research collaboration and initiation of the ALCMI-006 study, which was developed and will be conducted by ALCMI and its consortium of leading U.S. and international oncology centers. This global study will focus on patients whose tumors contain a ROS1 gene rearrangement, with the goal to develop new models to study this uncommon yet clinically important genotype of cancer.

Click here to read the full press release

About Guneet Walia, PhD

Dr. Guneet Walia is here to serve as your guide through what can feel like an overwhelming amount of information and jargon in lung cancer research. With her extensive background in oncology & drug development in the lab and experience working with cancer patients, she culls through the latest news to bring you the most important developments that can impact you and your disease today. If you have any questions, please don't hesitate to get in touch with Dr. Walia.

Comments are closed.